Corcept Therapeutics (CORT) on Wednesday said the U.S. Food and Drug Administration has issued a Complete Response Letter for the New Drug Application of relacorilant to treat hypertension secondary to hypercortisolism.
While the FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the GRADIENT study provided supportive evidence, the agency said additional proof of effectiveness is needed to support a favorable benefit-risk assessment.
CORT is currently trading at $33.81, down $36.38 or 51.83 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.